| Literature DB >> 17937985 |
Xianghong Wang1, Partha P Chakrabarti, Vassil I Ognyanov, Liping H Pettus, Rami Tamir, Helming Tan, Phi Tang, James J S Treanor, Narender R Gavva, Mark H Norman.
Abstract
A series of trisubstituted pyrimidines were synthesized to improve aqueous solubility of our first TRPV1 clinical candidate (1; AMG 517), while maintaining potent TRPV1 inhibitory activity. Structure-activity and structure-solubility studies led to the identification of compound 26. The aqueous solubility of 26 (>or=200microg/mL, 0.01 HCl; 6.7microg/mL, phosphate buffered saline (PBS); 150microg/mL, fasted-state simulated intestinal fluid (SIF)) was significantly improved over 1. In addition, compound 26 was found to be orally bioavailable (rat F(oral)=24%) and had potent TRPV1 antagonist activity (capsaicin IC(50)=1.5nM) comparable to that of 1.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17937985 DOI： 10.1016/j.bmcl.2007.09.080
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823